Last Updated : May 11, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name Sort descending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Ibrance (with Faslodex) | Palbociclib (with Fulvestrant) | Palbociclib (Ibrance) in combination with fulvestrant for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Invega | Paliperidone | Schizophrenia | Do not list | Complete | ||
| Invega Sustenna | Paliperidone palmitate | Schizophrenia | Do not list | Complete | ||
| Aloxi (capsule) | Palonosetron | Chemotherapy-induced nausea and vomiting | Withdrawn | |||
| Aloxi (injection) | Palonosetron hydrochloride | Chemotherapy-induced nausea and vomiting | Do not list at the submitted price | Complete | ||
| Aloxi (capsule) | Palonosetron hydrochloride | Chemotherapy-induced nausea and vomiting | Do not list | Complete | ||
| Sohonos | palovarotene | Fibrodysplasia Ossificans Progressiva | Reimburse with clinical criteria and/or conditions | Complete | ||
| Vectibix | Panitumumab | Metastatic Colorectal Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Vectibix | Panitumumab | Left Sided Metastatic Colorectal Cancer (mCRC) | Do not reimburse | Complete | ||
| N/A | panitumumab | Left-sided metastatic colorectal cancer (mCRC) | Reimburse with clinical criteria and/or conditions | Active |
Last Updated : May 11, 2024